Advanced Harm Reduction Collaborative

The Enhanced Harm Reduction Working Group is a coalition of scientists, researchers, policymakers, treatment professionals, and advocacy organizations, united in their efforts to minimize the risks associated with intravenous drug use.

Aim

The aim of the Enhanced Harm Reduction Working Group is to develop and implement evidence-based strategies to reduce the negative health and social impacts of intravenous drug use, while promoting safe practices, access to treatment, and supportive policies.

Objectives

Promote Public Health: Develop strategies to reduce the transmission of infectious diseases and other health risks associated with intravenous drug use.
Advocate for Evidence-Based Policy: Support the creation of policies that prioritize harm reduction, providing access to safe drug use practices, treatment, and recovery resources.
Collaborate Across Sectors: Foster partnerships between scientists, healthcare providers, policymakers, and advocacy groups to create a unified approach to harm reduction.
Enhance Treatment Access: Increase availability and accessibility of treatment programs, including medication-assisted therapy, detoxification services, and counseling.
Educate and Raise Awareness: Promote education about harm reduction principles, safe injection practices, and available resources to reduce stigma and encourage healthier behaviors.
Conduct Research: Support ongoing research to better understand the causes, consequences, and effective solutions for intravenous drug use-related harms.
Advocate for Social Equity: Address the social determinants of health that contribute to intravenous drug use and promote social policies that reduce harm and enhance quality of life for affected individuals.

Rationale

The rationale behind the Enhanced Harm Reduction Working Group is rooted in the understanding that intravenous drug use poses significant public health challenges, including the transmission of infectious diseases such as HIV and hepatitis, overdose deaths, and social stigmatization. Traditional approaches focused solely on prevention and abstinence have not been fully effective in addressing the complexities of this issue. Harm reduction strategies, which aim to reduce the negative consequences of drug use rather than criminalize or punish individuals, are proven to improve health outcomes, save lives, and promote safer communities. By bringing together scientific experts, policymakers, healthcare providers, and advocacy groups, this consortium seeks to implement data-driven, compassionate approaches that protect the well-being of individuals and communities while reducing the broader societal impacts of intravenous drug use.

Collaborations

We are working together with a trusted group of Contract Research Organisations and have established partnerships with the leading academic institutions in the UK as well as a range of external experts globally.

What we offer

Project Management

Scoping Reviews
Project Coordination
Scientific Due Diligence
Grant Writing

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Conducting Research

Qualitative Research
Cross Sectional and Longitudinal Surveys
Real World Evidence Collection and Analysis
Statistical Analysis

Clinical Trial Development

Literature Reviews
Protocol Development for Clinical Trials
Clinical Trial Project Management
Navigating Regulatory Process